Fine chemical

Europe Laboratory Information Management System (LIMS) Market Insights Report 2023-2028: Rise in Remote Access Needs Boosts Cloud-Based LIMS Adoption Across Europe

Retrieved on: 
Friday, February 16, 2024

DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Europe Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Europe Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • This report offers market size & forecast data for the Europe laboratory information management system (LIMS) market.
  • The laboratory information management system (LIMS) is a software-based laboratory and information management system which supports modern laboratory operations.
  • Who are the key players in the Europe laboratory information management system (LIMS) market?

Pressure BioSciences Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing

Retrieved on: 
Thursday, February 15, 2024

The new building is currently being transformed into a state-of-the-art manufacturing facility.

Key Points: 
  • The new building is currently being transformed into a state-of-the-art manufacturing facility.
  • The state-of-the-art facility is to be equipped with the latest modern utilities and amenities, and will house dedicated areas for R&D, equipment production, formulation services, and product manufacturing.
  • Ken Micciche, PBIO’s Director of Business Development, commented: “We are very excited about the opportunities this consolidation and expansion presents.
  • This will enable PBIO to expand production capacity in UltraShear equipment installations, while maintaining stringent quality control and ensuring the total reliability of its products.

INCOG BioPharma Services adds 100 million units of syringe/cartridge capacity

Retrieved on: 
Thursday, February 15, 2024

FISHERS, Ind., Feb. 15, 2024 /PRNewswire/ -- INCOG BioPharma Services, a US-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity.

Key Points: 
  • FISHERS, Ind., Feb. 15, 2024 /PRNewswire/ -- INCOG BioPharma Services, a US-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity.
  • It will complement the company's existing multi-use filling line, bringing the company's total filling capacity to 140 million units per year.
  • In addition to the new filling line, INCOG recently added automated visual inspection capabilities and will soon complete qualification of equipment to support auto-injector device assembly services.
  • The decision to increase capacity, well before current capacity limits were reached, was based on a business philosophy that prioritizes customer needs.

CYTENA Launches The 2nd Generation UP.SIGHT And C.STUDIO - An All-in-one Solution for Industrial Cell Line Development Revolutionizing the Manufacturing of Biologics

Retrieved on: 
Thursday, February 15, 2024

FREIBURG, Germany, Feb. 15, 2024 /PRNewswire-PRWeb/ -- CYTENA GmbH, a BICO company and a global leader in single cell dispensing technologies, is pleased to announce the launch of the 2nd generation UP.SIGHT - a transformative single-cell dispenser and imager ushering in a new era in stable cell line development workflows.

Key Points: 
  • CYTENA GmbH, a subsidiary of BICO and a leading figure in single cell dispensing technologies, has recently unveiled the 2nd generation UP.SIGHT.
  • The system also introduces the C.STUDIO software, a sophisticated platform for data analysis and reporting tailored to cell line development.
  • CYTENA is also introducing an advanced CLD (Cell Line Development) analysis suite called C.STUDIO, alongside the new generation of UP.SIGHT.
  • It also features comprehensive reporting tools for regulatory submissions, making it the most sophisticated software designed specifically for enhancing cell line development workflows.

SkinCeuticals Announces the Launch of Cell Cycle Catalyst

Retrieved on: 
Thursday, February 15, 2024

NEW YORK, Feb. 15, 2024 /PRNewswire/ -- SkinCeuticals, the #1 Medical Skincare Brand, announces the launch of Cell Cycle Catalyst. This new, innovative lightweight serum was developed to improve the efficacy of anti-aging treatments, both at home and in-office.

Key Points: 
  • NEW YORK, Feb. 15, 2024 /PRNewswire/ -- SkinCeuticals, the #1 Medical Skincare Brand, announces the launch of Cell Cycle Catalyst.
  • SkinCeuticals Cell Cycle Catalyst addresses key signs of aging head-on, providing a comprehensive solution to accelerate cellular turnover, boost cellular energy and vitality, stimulate barrier renewal, and eliminate dead surface cells.
  • "SkinCeuticals Cell Cycle Catalyst represents the next evolution in skincare innovation," says Angela Hildebrand, General Manager of SkinCeuticals U.S. "Cell Cycle Catalyst exemplifies our positioning as a pioneer in cosmeceuticals and our dedication to delivering transformative results to our customers both at-home and in tandem with their clinical procedures in-office."
  • "Cell Cycle Catalyst triggers 'cell cycling,' to eliminate dead skin cells and activate new skin cells, resulting in amplified at-home skincare benefits and increased receptivity of in-office clinical procedures."

ngrok Transforms API Delivery with the Industry’s First Developer-Defined API Gateway

Retrieved on: 
Thursday, February 15, 2024

SAN FRANCISCO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ngrok, the secure unified ingress platform for developers, today unveiled early access to its API gateway-as-a-service that marks a major advancement in how APIs are delivered.

Key Points: 
  • With this new capability, ngrok transforms API delivery by putting developers in control.
  • “ngrok’s API gateway-as-a-service represents a major milestone that effectively bridges the gap between deployable and cloud-based solutions,” said Alan Shreve, founder and CEO of ngrok.
  • ngrok addresses these challenges with its innovative, developer-centric approach to API delivery, leading to the following outcomes:
    Faster delivery: ngrok integrates ingress directly into applications, allowing developers to establish secure API connectivity with a single command or line of code.
  • Reduced risk: By embedding ingress into the application itself, ngrok ensures that API requests contain all the necessary parameters expected by the API.

BioHarvest Sciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

Retrieved on: 
Thursday, February 15, 2024

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 15, 2024) - BioHarvest Sciences Inc. , (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company"), a biotechnology company pioneering botanical synthesis, has engaged investor relations specialists MZ Group (MZ) to lead a strategic investor relations and financial communications program across all key markets.

Key Points: 
  • Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 15, 2024) - BioHarvest Sciences Inc. , (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company"), a biotechnology company pioneering botanical synthesis, has engaged investor relations specialists MZ Group (MZ) to lead a strategic investor relations and financial communications program across all key markets.
  • MZ will work closely with BioHarvest management to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community.
  • The company's first commercialized grape-derived product, VINIA®, is driving strong revenue growth as BioHarvest continues the launch of incremental product lines.
  • Individuals performing the services at MZ will be entitled to receive consultant options when granted by the board of BioHarvest.

Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company

Retrieved on: 
Thursday, February 15, 2024

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce it has entered into a research collaboration with a multi-national European-based pharmaceutical company (“Collaborator”).

Key Points: 
  • TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce it has entered into a research collaboration with a multi-national European-based pharmaceutical company (“Collaborator”).
  • The research collaboration will initially assess the Company’s proprietary SEDDS technology in combination with Collaborator’s various drug delivery and pharmaceutical formats to gain a better understanding of proprietary dosage forms with precisely standardized delivery and enhanced bioavailability of cannabinoids.
  • The research collaboration may subsequently assess the possibility of further preclinical research and clinical development.
  • Under the research collaboration, Avicanna will also provide services for assessing a range of other formulations that may be included in Collaborator’s portfolio.

Firefly Bio Debuts With $94 Million Series A Financing

Retrieved on: 
Thursday, February 15, 2024

Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.

Key Points: 
  • Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.
  • Firefly has developed a novel platform to treat cancer using degrader antibody conjugates (DACs).
  • Firefly was incubated in close collaboration with scientists at Versant’s Ridgeline Discovery Engine in the Basel Technology Park.
  • “At Firefly, we’ve assembled a unique talent base and platform to significantly advance this promising field,” said Jerel Davis, Ph.D., Managing Director at Versant and a Firefly board member.

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Retrieved on: 
Thursday, February 15, 2024

Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced an important milestone in its antibody-drug conjugate (ADC) program.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced an important milestone in its antibody-drug conjugate (ADC) program.
  • In collaboration with Bielefeld University, Lantern has generated a new class of highly specific and highly potent ADCs with a cryptophycin drug-payload.
  • View the full release here: https://www.businesswire.com/news/home/20240215526567/en/
    Preclinical results from Lantern's cryptophycin ADC (Cp-ADC) in HER2 expressing cancers in comparison with commercially available MMAE payload antibody-drug conjugates (ADCs).
  • These efforts aim to improve ADC development for specific patient populations and potentially guide more effective future clinical treatments with less cost and greater efficiency than historical ADC drug development.